Significant Progress Achieved in Marine-Derived NLRP3 Inflammasome Inhibitor Research
Recently, the team led by Prof. Li Dehai from OUC’s School of Medicine and Pharmacy, the MoE Key Laboratory of Marine Drugs, the Marine Drugs and Biological Products Function Laboratory of Qingdao Marine Science and Technology Center, and the Marine Biomedical Research Institute of Qingdao, has made significant advances in marine-derived NLRP3 inflammasome inhibitors. The research findings have been published in the prestigious journals Journal of the American Chemical Society and Angewandte Che